In colorectal cancer, the OS and recurrence-free survival rates of patients with increased ZEB1-AS1 expression were lower, indicating that ZEB1-AS1 is a promising biomarker in predicting the clinical outcome [44]. The gene discussed is ZEB1; the disease is colorectal cancer.